Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients.

Vasc Health Risk Manag · 2019 · PMC6593743 · PMID 31417269

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Clinically relevant non-major bleeding (CRNMB) was also higher in the edoxaban arm (14.6%) compared with the dalteparin arm (11.1%), but this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.